



Nanoparticles for Transmucosal Delivery of CRISPR-based Gene Editing Tools in the Lung

Belal Tafech


Supervisor: Dr. Sarah Hedtrich

July 13th 2022




Background: The airway mucus layer

- A thin layer of fluid covering the lung epithelium
- Traps inhaled particles from penetrating into the epithelium
- Subdues delivery of promising therapeutics for pulmonary diseases
- Cystic Fibrosis



A promising therapy for Cystic Fibrosis


- Cystic Fibrosis (CF)
 - Monogenetic disorder
 - CFTR gene
 - Current medication
 - Median age of death is 33yrs in Canada
- CRISPR-Cas9: A revolutionary therapy



The challenge remains in efficiently delivering genetic cargo across the mucus

Airway mucus barrier mechanisms

- **Physical barrier**
 - Mucin polymers and other mucus contents form a porous network




Average pore size

- Healthy: 200nm
- CF: < 150nm

Airway mucus barrier mechanisms

- **Biochemical barrier**
 - Glycan chains that terminate in negatively charged residues such as sialic acid (green)




Overall Research Objectives

Research goals:

1. Determining nanoparticle (NP) characteristics for efficient transmucosal gene delivery in healthy and disease states of the lung
2. Assessing NPs uptake and gene editing efficacy in primary lung epithelial cells

Nanoparticle Tracking Analysis (NTA)




- The NTA method relies on capturing videos of live NP movement in mucus
- The videos recorded are further analyzed using computer software to obtain median diffusion coefficients of NPs in mucus


Assessing NP + gene editing cargo diffusivity in mucus

- Lipid nanoparticles (LNPs) encapsulating CRISPR-Cas9 in the form of either
 - mRNA: LNP-mRNA (~50nm)
 - Ribonucleoprotein (RNP) complex: LNP-RNP (~260nm)
- Compared LNP-mRNA vs LNP-RNP diffusivity in mucus using NTA method

LNP-mRNA vs LNP-RNP in lung mucus



LNP-mRNA
In mucus




LNP-RNP
In mucus

LNP-mRNA (Blue) vs LNP-RNP (Red)

Name	Median Diffusion Coefficient
LNP-mRNA	$0.68 (\mu\text{m})^2/\text{s}$
LNP-RNP	$0.31 (\mu\text{m})^2/\text{s}$

- LNP-mRNA has a 2.19 fold increase in median diffusion coefficient
- At least partially due to LNP-mRNA (~50nm) smaller size than LNP-RNP (~260nm)




Testing LNP transport in Cystic Fibrosis mucus

LNP-mRNA vs LNP-RNP in Cystic Fibrosis (CF) mucus



LNP-mRNA







LNP-RNP

- The movement of the LNPs was drastically halted in CF mucus
- Factors other than size must be considered

Impact of sialic acid on capsid diffusivity in mucus

- Mucin has glycan chains that terminate in negatively charged sialic acid residues (green)
- Enhances the trapping of charged particles
- Removed sialic acid from mucin using neuraminidase (NA) at different levels:





¹Schuster BS *et al.* Biomaterials. 2013;34(13):3439-3446

²Petrou G & Crouzier T. Biomater. Sci. 2018(6): 2282-2297

Impact of sialic acid removal on diffusivity

- Capsids with small sizes ($\sim 20\text{nm}$) were added to mucus & NTA was performed



- Increase in NP diffusivity with higher % of SA removed in both healthy and CF mucus conditions

Goal 2. Assessing LNP uptake and gene editing efficacy
in primary lung epithelial cells

Assessing the transfection efficiency of LNPs in primary lung epithelial cells

- Lipid nanoparticles (LNPs) loaded with mRNA encoding GFP
- Transfected into normal human bronchial epithelial (NHBE) cells
- Successful transfection results in:
 - GFP-mRNA is translated into a GFP protein
 - A green fluorescence can be detected
 - Imaged using fluorescence microscope




NHBEs transfected with LNPs + eGFP-mRNA

Hoechst (nuclear stain)




GFP (green)

Merged

LNP A
1ug/mL




LNP B
1ug/mL




Gene editing efficacy in primary lung epithelial cells

- LNPs are loaded with
 - CRISPR-Cas9 mRNA or protein
 - SgRNA against HPRT
- Transfected in the primary lung cells
 - Normal human bronchial epithelial (NHBEs) cells
- Real-time PCR: Quantify relative HPRT Indel (insertion or deletion) percentages




Treating NHBE cells with LNPs + CRISPR-Cas9 mRNA or RNP



- Around 5% gene editing only
- Cas9 RNP appears slightly more potent than Cas9 mRNA

Treating NHBE cells with CRISPR-Cas9 mRNA or RNP



- Increasing sgRNA to Cas9-protein ratio to 5:1
- Around 10% gene editing
- As sgRNA is degraded faster than Cas9 protein
 - More sgRNA helps overcome this

Conclusions

- LNP-mRNA showed the highest diffusion in isolated healthy lung mucus
- Mucus isolated from Cystic Fibrosis patients halts the diffusion of LNPs
- Sialic acid removal improves NP diffusivity in healthy and CF conditions
- On the cellular level, LNPs show high uptake in primary lung epithelial cells
- Increasing ratio of sgRNA to Cas9 protein (5:1) improves gene editing

Acknowledgement:
Thank you!

- Dr. Sarah Hedtrich
 - Partho Adhikary
 - Selina Shanta
 - Fatemeh Mohabatpour
 - Zheng (Maomao) Tan
 - Juliana Bolsoni
 - Leah Mappalakayil
 - Gaëlle Wagner
 - Ronja Ebner
 - Danny Liu
- NanoVation Therapeutics
 - Jayesh Kulkarni
- Dr. Pieter Cullis lab
 - Jerry Leung
- Acuitas Therapeutics
 - Molly Sung
 - Paulo Lin
 - Ying Tam
- Dr. Christian Hackenberger (FMP, Berlin)
- Jack Bell Research Centre
 - Stephanie Smith
- St. Paul's Hospital
 - Ekjot Sangha
 - Jiah Jang





Thank you!

Questions